IP Library Granted Patent US 11,639,523
Granted Patent B2
US 11,639,523 · App. 16/894,678 · Granted May 2, 2023

Type V CRISPR-Cas systems and use thereof

Inventors: Feng Zhang (Cambridge, MA); Jonathan Gootenberg (Cambridge, MA); Omar Abudayyeh (Cambridge, MA); Julia Joung (Cambridge, MA); Alim Ladha (Cambridge, MA); Han Altae-Tran (Cambridge, MA); Guilhem Faure (Cambridge, MA)
Assignees: THE BROAD INSTITUTE, INC.; MASSACHUSETTS INSTITUTE OF TECHNOLOGY
C12Q1/6844B01L3/502715B01L7/52C12N9/1276C12N9/22C12N9/78C12Q1/6806B01L2300/0816C12N2310/20C12Q2600/156C12Q2600/16C12Y207/07049G01N2333/165
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,639,523
App. No.
16/894,678
Granted
May 2, 2023
Kind
B2
Abstract

Engineered or non-naturally occurring systems and compositions comprising a novel Cas12b and a guide molecule. Also provided include methods of use the systems and compositions, including in treating and diagnosing diseases.

Claims (18)

1. A non-naturally occurring or engineered composition comprising

a Cas12b protein from Alicyclobacillus acidiphilus ; and

a guide molecule that does not impede the Cas12b's activity at elevated temperatures above 55° C., comprising a guide sequence with at least 95% or more sequence similarity to a direct repeat and tracrRNA sequence from the Alicyclobacillus acidoterrestris CRISPR-Cas12b system and capable of forming a complex with the Cas12b protein and directing the complex to bind to a target polynucleotide.

2. The composition of claim 1 , wherein the guide sequence comprises one of SEQ ID NOs: 61957-61961.

3. The composition of claim 1 , wherein the Cas12b protein is fused to one or more localization signals.

4. The composition of claim 1 , further comprising a detection construct comprising a non-target polynucleotide, wherein the Cas protein exhibits collateral activity and cleaves the non-target polynucleotide component once activated by the target polynucleotide.

5. The composition of claim 4 , further comprising one or more isothermal amplification reagents.

6. The composition of claim 5 , wherein the isothermal amplification reagents are loop-mediated isothermal amplification (LAMP) reagents, wherein the LAMP reagents are primers selected from SEQ ID NOs: 61983-61988.

7. The composition of claim 6 , wherein the guide molecule is designed to bind to a polynucleotide sequence of SARS-CoV-2, wherein the guide molecule is SEQ ID NO: 61989.

8. A vector composition comprising one or more polynucleotide sequences encoding the Cas12b protein and the guide molecule in the composition of claim 1 .

9. A non-naturally occurring or engineered prokaryotic or eukaryotic isolated host cell comprising the composition of claim 1 , or progeny thereof.

10. A method of targeting one or more target polynucleotides, the method comprising contacting the one or more target polynucleotides with a non-naturally occurring or engineered composition of claim 1 , wherein targeting comprises modifying the one or more target polynucleotides comprises increasing or decreasing expression of the one or more genes in the one or more target polynucleotides, insertion of a recombination template or a portion thereof to the one or more target polynucleotides.

11. A method for detecting a target polynucleotide in a sample, comprising

contacting the sample with the composition of claim 4 , wherein the Cas protein exhibits collateral activity and cleaves the detection construct once activated by the target polynucleotide, and the cleaved detection construct generate a signal; and

detecting the signal thereby determining presence of the target polynucleotide in the sample.

12. A kit for modifying or detecting a target polynucleotide in a sample, comprising the composition of claim 1 .

13. The composition of claim 1 , wherein the guide molecule comprises a sequence with at least 95% or more sequence similarity to one of SEQ ID NOs: 61957-61961.

14. The vector composition of claim 8 , wherein the polynucleotide sequences are codon optimized for expression in a eukaryotic cell.

Assignments (9)
CONFIRMATORY LICENSE Recorded Oct 2, 2023
From: BROAD INSTITUTE, INC.
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065091/0692 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2021
From: ZHANG, FOR HIMSELF AND AS AGENT OF HOWARD HUGHES MEDICAL INSTITUTE, FENG
To: THE BROAD INSTITUTE, INC.; MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 055674/0444 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2021
From: ZHANG, FENG
To: HOWARD HUGHES MEDICAL INSTITUTE
Reel/Frame 055641/0780 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2020
From: ALTAE-TRAN, HAN
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 054566/0673 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2020
From: FAURE, GUILHEM
To: THE BROAD INSTITUTE, INC.
Reel/Frame 053875/0691 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2020
From: LADHA, ALIM
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 053863/0069 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2020
From: JOUNG, JULIA
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 053791/0041 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 16, 2020
From: GOOTENBERG, JONATHAN
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 053223/0987 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 16, 2020
From: ABUDAYYEH, OMAR
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 053223/0966 →
Continuity (5)
Provisional Application 62993494 · Mar 23, 2020
Provisional Application 63018487 · Apr 30, 2020
Provisional Application 63019406 · May 3, 2020
Provisional Application 63032470 · May 29, 2020
Related Publication 20210292721A1 · Sep 23, 2021
Cited By (3)
US 12,662,667 US 12,686,862 US 12,709,778